Drugs / Fanhdi
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02472665 | Dec 2013 → Dec 2024 | hereditary von Willebrand disease | Grifols Therapeutics LLC | Withdrawn | No outcome recorded Stop: Enrollment |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-22 | Grifols Therapeutics LLC | Results Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease grifols.com ↗
Grifols’ Fanhdi showed it could be effective, safe and well tolerated in the management of bleeding episodes and for the prevention of bleeding during surgeries in patients with von Willebrand Disease (VWD) |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-22 | Grifols Therapeutics LLC | Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease grifols.com ↗ |
| 2024-04-22 | Grifols Therapeutics LLC | Grifols achieves positive results from phase 4 study of Fanhdi® (double-inactivated human anti-hemophilic factor) in patients with von Willebrand Disease grifols.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fanhdi | “1 single dose of 80 IU/kg VWF:RCo of Fanhdi will be administered” NCT02472665 ↗ |
| Modality | Protein / enzyme biologic | “Fanhdi (high-purity Von Willebrand containing FVIII concentrate)” NCT02472665 ↗ |